Equitable (EQH) Q3 2025 Earnings Transcript

Equitable reported $455 million of non-GAAP operating earnings, or $1.48 per share, with adjusted EPS of $1.67, up 2% year over year after notable items. Assets under management hit a record $1.1 trillion, retirement net flows were $1.1 billion, wealth management net inflows were $2.2 billion, and AllianceBernstein adjusted margin expanded 290 bps to 34.2%. Management kept its 12% to 15% EPS CAGR target through 2027, reiterated strong capital return plans, and announced the Stifel Independent Advisors acquisition plus a $100 million investment in FCA Re.

Analysis

EQH is transitioning from a balance-sheet story to an operating leverage story: the market should start valuing the mix shift more than the noisy GAAP optics. The key second-order effect is that every dollar of capital recycled out of legacy life/reinsurance into wealth, private markets, and buybacks compounds twice — first via higher fee intensity, then via lower share count — which should make 2026 the first year the market can clearly underwrite the 2027 EPS target rather than merely trust it.

The underappreciated bullish signal is not the headline growth, but the durability of the cash engine outside insurance. Management is now effectively saying more than half of organic cash generation comes from asset/wealth, which reduces dependence on spread and mortality variables and should compress the discount to peers with cleaner fee mix. That also makes the equity more resilient to rate cuts than the market may think; the direct cash-sweep sensitivity is modest, while AUM-driven fee expansion and capital deployment should more than offset it over a 6-18 month horizon.

The main risk is not earnings quality, but valuation discipline on the capital deployment program. If private credit credit spreads tighten further, or if competitive pressure in RILA forces richer guarantees/caps, the IRR on the growth investments could fall faster than consensus models today. The contrarian read is that the market may be over-focusing on insurance headline risk and underpricing the reinvestment optionality; however, if acquisition discipline slips or if sidecar/alternative bets become a larger share of capital allocation, EQH could migrate from a rerating candidate to a capital-allocation debate.

RGA is the cleaner relative loser: EQH has de-risked and recycled capital, while RGA has picked up the lower-return block economics and potentially some complexity without the same growth flywheel. BLK is a mild beneficiary via broader private-market validation, but the more important competitive implication is that EQH can source growth-capital internally rather than paying external managers' carry economics.

Key Decisions for Investors

• Go long EQH on a 3-6 month horizon; thesis is a rerating as the market begins to price 2026 cash generation and buyback support rather than GAAP noise. Target is mid-teens upside if execution holds; downside is limited unless capital deployment disappoints.
• Pair trade long EQH / short RGA for the next 2-4 quarters. EQH has the cleaner mix shift, stronger buyback cadence, and more visible EPS compounding; RGA is more exposed to lower-return reinsurance economics and less explicit capital return acceleration.
• Add EQH on any post-earnings pullback below a near-term technical support level if it coincides with continued buybacks. Risk/reward improves materially because the company is still retiring shares while de-risking legacy volatility.
• For more convex exposure, buy EQH 6-9 month calls rather than stock if implied vol remains reasonable. The catalyst stack is sequential: capital return completion, 2026 cash-flow guidance, and continued AB/private-markets monetization.
• Avoid chasing BLK as a read-through trade; the linkage is indirect. If you want private-markets beta, EQH offers the better asymmetric setup because the platform economics are embedded in the parent-level capital allocation story.